Skip to main content
Bio-Thera Solutions, Ltd. logo

Bio-Thera Solutions, Ltd. — Investor Relations & Filings

Ticker · 688177 ISIN · CNE100003R98 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 691 across all filing types
Latest filing 2022-02-11 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 688177

About Bio-Thera Solutions, Ltd.

https://www.bio-thera.com/

Bio-Thera Solutions, Ltd. is a biopharmaceutical company dedicated to the research and development of innovative therapeutics and high-quality biosimilars. The company focuses on addressing serious medical conditions across oncology, autoimmune, and cardiovascular therapeutic areas. Its portfolio includes several approved biosimilars, such as QLETLI (adalimumab), POBEVCY (bevacizumab), and TOFIDENCE (tocilizumab), alongside a robust pipeline of novel drug candidates, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Bio-Thera utilizes advanced technology platforms to streamline the drug discovery and development process, aiming to expand global access to essential biologic medicines. The organization maintains a commitment to rigorous clinical standards and international regulatory compliance to deliver effective treatment options for patients worldwide.

Recent filings

Filing Released Lang Actions
百奥泰 首次公开发行战略配售限售股上市流通公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the listing and circulation of restricted shares (限售股) related to the company's initial public offering (IPO) strategic placement shares. It details the number of shares becoming tradable, the lock-up period, shareholder commitments, and regulatory approvals. There is no financial data or report content, but rather a formal notification about share circulation status. This fits the category of Share Issue/Capital Change announcements, as it concerns the change in share capital availability and circulation status after IPO lock-up expiration.
2022-02-11 Chinese
百奥泰 2021年年度业绩预盈公告
Earnings Release Classification · 95% confidence The document is titled as a 2021 annual performance forecast announcement by 百奥泰生物制药股份有限公司. It provides preliminary estimated net profit figures for the full year 2021, comparing them to the previous year, and explicitly states that the forecast is unaudited and that the final audited figures will be in the formal annual report. The document is short (1374 characters) and serves as a performance preview or earnings guidance rather than a full financial report. It does not contain detailed financial statements or comprehensive analysis, only preliminary profit estimates and business highlights. Therefore, it fits the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. FY 2021
2022-01-27 Chinese
百奥泰 关于就BAT1706（贝伐珠单抗）签署授权、分销、供货协议收到里程碑付款的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 百奥泰生物制药股份有限公司 regarding the receipt of milestone payments under an authorization, distribution, and supply agreement for a pharmaceutical product (BAT1706). It details the agreement terms, payment amounts, dates, and potential impacts on company performance. The document is relatively short (1239 characters) and focuses on a financing-related update about milestone payments received, not a full financial report or earnings release. There is no indication of it being a full annual or interim report, audit report, or earnings release. It is an update on capital inflow related to licensing and milestone payments, which fits the Capital/Financing Update category.
2021-12-30 Chinese
百奥泰自愿披露关于阿达木单抗注射液获得药品补充申请批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement from 百奥泰生物制药股份有限公司 regarding the approval of a supplemental drug application for a new indication and specification of their product 阿达木单抗注射液 (Adalimumab Injection). It includes details about the drug, regulatory approval from the National Medical Products Administration, and risk disclosures. The document is short (1118 characters) and serves as a formal notification of regulatory approval rather than a detailed financial or operational report. It does not contain financial statements, management discussion, or detailed investor presentation content. It is not an earnings release, annual report, or interim report. It is also not a proxy, voting result, or board change announcement. The content fits best as a Regulatory Filing (RNS) because it is a regulatory announcement about drug approval and related risks, which does not fit other more specific categories.
2021-12-13 Chinese
百奥泰 关于5%以上股东减持时间过半的进展公告
Major Shareholding Notification Classification · 100% confidence The document is a formal announcement from 百奥泰生物制药股份有限公司 regarding the progress of a shareholding reduction plan by shareholders holding more than 5% of the company's shares. It details the shareholders involved, the number of shares held and reduced, the timeline of the reduction plan, and the impact on the company. The document does not contain financial statements or detailed financial analysis but focuses on the status and progress of a significant shareholding change. This fits the definition of a Major Shareholding Notification (MRQ), which involves notifications of changes in significant share ownership levels. The document length is 3080 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is MRQ.
2021-12-06 Chinese
百奥泰 关于公司贝伐珠单抗注射液（普贝希？）获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from 百奥泰生物制药股份有限公司 regarding the approval of a drug registration certificate for their product 贝伐珠单抗注射液 (普贝希®) by the National Medical Products Administration (NMPA) of China. It details the drug's specifications, regulatory approval, market context, and cooperation agreements for commercialization. The document does not contain financial statements, earnings data, or detailed financial analysis. It is a regulatory announcement about a product approval and related business developments, not a financial report or earnings release. The document length is about 2032 characters, which is relatively short and consistent with an announcement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-11-19 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.